PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 178 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $271,000 | +32.8% | 7,000 | -30.0% | 0.05% | +16.7% |
| Q4 2018 | $204,000 | -55.5% | 10,000 | 0.0% | 0.04% | -46.2% |
| Q3 2018 | $458,000 | -22.6% | 10,000 | 0.0% | 0.08% | -26.4% |
| Q2 2018 | $592,000 | -12.9% | 10,000 | 0.0% | 0.11% | -12.4% |
| Q1 2018 | $680,000 | -14.0% | 10,000 | +25.0% | 0.12% | -11.7% |
| Q4 2017 | $791,000 | -26.6% | 8,000 | -11.1% | 0.14% | -29.7% |
| Q3 2017 | $1,078,000 | +146.7% | 9,000 | +80.0% | 0.20% | +137.8% |
| Q2 2017 | $437,000 | +28.2% | 5,000 | -45.5% | 0.08% | +26.2% |
| Q1 2017 | $341,000 | +20.9% | 9,167 | 0.0% | 0.06% | +16.1% |
| Q4 2016 | $282,000 | -54.1% | 9,167 | 0.0% | 0.06% | -55.9% |
| Q3 2016 | $614,000 | +124.9% | 9,167 | 0.0% | 0.13% | +119.0% |
| Q2 2016 | $273,000 | -6.5% | 9,167 | 0.0% | 0.06% | -6.5% |
| Q1 2016 | $292,000 | -59.4% | 9,167 | 0.0% | 0.06% | -57.8% |
| Q4 2015 | $719,000 | +4.1% | 9,167 | 0.0% | 0.15% | -1.3% |
| Q3 2015 | $691,000 | – | 9,167 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,300,000 | $13,338,000 | 2.17% |
| Camber Capital Management LP | 2,555,000 | $26,214,000 | 0.92% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,959,741 | $40,627,000 | 0.80% |
| Palo Alto Investors LP | 1,373,897 | $14,096,000 | 0.74% |
| Sofinnova Investments, Inc. | 629,650 | $6,460,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 604,937 | $6,207,000 | 0.22% |
| J. Goldman & Co LP | 238,617 | $2,448,000 | 0.12% |
| GLOBEFLEX CAPITAL L P | 55,027 | $565,000 | 0.12% |
| FRED ALGER MANAGEMENT, LLC | 3,416,003 | $35,048,000 | 0.09% |
| JUPITER ASSET MANAGEMENT LTD | 728,440 | $7,474,000 | 0.08% |